Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. 2018

Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.

Numerous studies concerning hepatic arterial infusion chemotherapy (HAIC) have been conducted by adopting regimens containing 5-fluorouracil (FU), with a favourable efficacy compared with conventional transcatheter arterial chemoembolisation (TACE) treatment; however, the detailed mechanism of HAIC remains unclear. The present study aimed to evaluate peripheral concentration time curves of 5-FU administered through the hepatic artery, which may additionally explain the mechanism of action of HAIC. A total of 10 eligible patients underwent transcatheter arterial embolization and a 2-day HAIC treatment regimen using a folinic acid, fluorouracil and oxaliplatin regimen. Peripheral venous blood sampling was performed in each patient prior to infusion, and at 0, 0.5, 1, 1.5, 2, 5, 10, 15, 22 and 23 h following the start of infusion. The blood sample at 0 h was analysed for dihydropyrimidine dehydrogenase (DPD) levels by high performance liquid chromatography, and the rest of the samples were analysed for 5-FU by optimised liquid chromatography-mass spectrometry (LC-MS). The lower limit of quantification of optimised LC-MS for 5-FU was 5 ng/ml. The steady-state plasma concentration of 5-FU administered through the hepatic artery was achieved after 15 h. This concentration largely varied, ranging from 8.64-152.00 ng/ml. Optimised LC-MS may detect low concentrations of 5-FU. The steady-state concentration of 5-FU administered through the hepatic artery was achieved after 15 h. DPD levels were analysed through determining the ratio of plasma uracil (U) and dihydrouracil (UH2) by HPLC, and the results indicated a mild DPD deficiency in the patients with HCC. These results may provide a basis for the explanation of the clinical efficacy of HAIC, and to additionally optimise its efficacy.

UI MeSH Term Description Entries

Related Publications

Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
January 2012, Asian Pacific journal of cancer prevention : APJCP,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
August 1988, American journal of clinical oncology,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
January 1967, Tumori,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
January 2003, Anticancer research,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
April 2001, Annals of oncology : official journal of the European Society for Medical Oncology,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
February 1989, Cancer,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
July 1995, British journal of cancer,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
May 1992, Cancer research,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
February 2014, Gan to kagaku ryoho. Cancer & chemotherapy,
Jian Gao, and Rui Zhen, and Hai Liao, and Wenquan Zhuang, and Wenbo Guo
February 2002, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!